Kornimate/medical-research-clean huggingface dataset:
evaluation of the benefit of the training of the manual dexterity post stroke.

Conditions: Cerebral Vascular Accident

Summary: stroke is the second leading cause of death and disability in france: more than half of stroke survivors have a disabling motor deficit, affecting mainly the upper limb. a lack of hand control makes everyday tasks more difficult and reduces the quality of life. the investigators lack approaches to specifically rehabilitate the hand after stroke. recently, a new tool has been developed to measure manual dexterity (the finger force manipulandum or ffm). this tool, which records the forces applied by the fingers on pistons, allows to measure more finely the key components of manual dexterity during visuomotor tasks. the tool measures the ability to control and release the force applied by the fingers, to perform sequences, to track and maintain a frequency of tapping (temporality of movement) with the fingers, and to use the fingers independently one another.

the dextrain proof-of-concept study aims to evaluate the benefit of a training using a tool, an improved version of the ffm, named dextrain, for the rehabilitation and specific training of the fingers in subjects suffering from stroke. in this study the investigators will compare the effect of conventional therapy with that of the dextrain method, particularly on the function of the hand and its spontaneous use at home (ecological condition). to better understand the mechanisms involved, the investigators will also study brain plasticity using transcranial magnetic stimulation (smt) and functional magnetic resonance imaging (fmri).

Eligibility criteria:
inclusion criteria: patient : * at least 18 years old * 1st symptomatic stroke, due to acute vascular injury (ischemic or haemorrhagic) affecting a single arterial territory dating from 3 months or more (multiple territory: corresponds to a bi-hemispheric or vertebrobasilar stroke and carotid for ischemic and bi-hemispherical stroke for hemorrhagic stroke) * with a slight-to-moderate deficit of manual dexterity, indicated by a difficulty in picking up blocks in the box and block test (\<52 blocks / minute, minimum 1 block) as well as an expansion capacity of 10 ° wrist and metacarpophalangeal joints of the index and middle finger. * affiliated to a social security scheme, universal health cover or any other equivalent plan. volunteers : * at least 18 years old * healthy subject of any disease affecting the hand, exclusion criteria: * significant disability or pre-existing deficiency that may interfere with study-specific assessments: • history of symptomatic stroke * disorders of the understanding not allowing a good comprehension of the tests of motor skills (severe aphasia, dementia, etc.) evaluated by the mmse (\<25) * botulinum toxin treatment of spastic muscles of the upper limb less than three months before inclusion and / or during rehabilitation (4 weeks). * another severe disease making follow-up difficult.
observational study on the outcome of aml patients treated with new drugs in real-life (boxtrial)

Conditions: Acute Myeloid Leukemia; AML, Adult; Acute Myeloid Leukemia, Adult

Summary: this multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult aml patients.

this multicenter, prospective and retrospective observational study (model: case only) aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult aml patients treated at italian gimema centers. no additional procedures or visits other than those required by normal clinical practice will be required. every patient will be followed for a minimum of 24 months.

Eligibility criteria:
inclusion criteria: 1. aged 18 years or older 2. aml diagnosis according to the eln guidelines, excluding m3 3. signed informed consent, if applicable 4. treatment initiation with novel drugs in monotherapy or combination, in accordance with the aifa authorizations, from the aifa registration up to 31.12.2027 with particular attention to: * patients affected by flt3-mutated aml treated with gilteritinib. * patients affected by idh-mutated aml treated with idh inhibitors. * patients affected by aml in maintenance therapy with oral azacytidine. * patients affected by aml treated with glasdegib. * patients affected by aml treated with gemtuzumab ozogamicin. * other novel drugs or combination for the treatment of aml approved during the study period. exclusion criteria: patients included in interventional clinical trials.
photodynamic therapy during supportive periodontal therapy

Conditions: Periodontal Diseases; Chronic Periodontitis; Periodontal Attachment Loss

Summary: 27 subjects on spt, each with at least two residual pockets ≥5mm, were recruited for this randomised, split-mouth controlled trial, providing a total of 72 sites. at baseline, probing pocket depth (ppd), recession, clinical attachment level (cal), plaque and bleeding on probing (bop) of all sites were examined. gingival crevicular fluid (gcf) were collected to determine level of cytokines il-1β, -6, -8, tnf-α and mmp-8 via elisa. control sites received subgingival instrumentation and rubber cup polishing with pumice. in addition test sites received a single application of pdt using fotosan® and photosensitizer consisting of toludine blue o solution. the subjects were recalled three and six months later and re-examined. site level analysis was performed.


Eligibility criteria:
inclusion criteria: 1. good general health with no systemic diseases causing manifestation of periodontal diseases 2. age ≥ 21 years 3. history of chronic periodontitis 4. at least two residual ppd ≥ 5 mm with or without bleeding on probing 5. compliant with recalls, i.e. last spt visit at most 6 months before start of trial 6. able to give written informed consent exclusion criteria: 1. pregnant or lactating females 2. local or systemic antibiotics intake in the past 3 months 3. systemic conditions which could affect progression of periodontitis 4. long term use of nsaids or immunosuppressive medications 5. participation in other clinical trials

Keywords: drug therapy photosensitizing agents therapeutic use
evaluation of bleeding score in egyptian patients with vwd type i and correlate it with laboratory parameters

Conditions: Von Willebrand Disease, Type 1

Summary: applying the isth-bat questionnaire on egyptian patients with type i vwd aiming to correlate the bs with the laboratory findings

the clinical phenotype of the disease is variable and tends to be mild in type 1 vwd, whereas it shows serious bleeding manifestations in types 2 and 3. overall, the symptoms reported in vwd include easy bruising, epistaxis, gastrointestinal bleeding, excessive menstrual bleeding, postpartum haemorrhage, and excessive bleeding after surgical operation and minor wounds.however, a distinctive bleeding history is a prerequisite for the diagnosis of any bleeding disorder and should guide further laboratory investigations in an attempt to standardize the diagnostic criteria of vwd, a bleeding questionnaire and a bleeding score were developed the combination of a standardized bleeding questionnaire and a well-defined interpretation grid (for the computation of the final (bs) has been referred to as a bleeding assessment tool (bat).

Eligibility criteria:
inclusion criteria: * type 1 vwd patients * healthy subjects with no known problem with bleeding or bruising were also recruited exclusion criteria: -

Keywords: von willebrand egyptian questionnaire
trial to determine the maximum tolerated dose of genexol-pm plus gemcitabine and evaluate efficacy and safety of genexol-pm regimens in subjects with advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a phase i/ii trial to determine the maximum tolerated dose and recommended phase ii dose of the combination therapy with genexol-pm and gemcitabine (hereafter genexol-pm plus gemcitabine) and to evaluate the efficacy and safety of genexol-pm regimens (monotherapy and combination with gemcitabine) and gemcitabine monotherapy in subjects with locally advanced or metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. subjects who aged 18 years or older 2. subjects whose written informed consent was obtained complying with the local regulatory requirements prior to their participation in the trial 3. subjects who have histologically or cytologically confirmed unresectable or metastatic epithelial cancer of the exocrine pancreas. high-quality contrast-enhanced ct scanning is required to evaluate resectability. measurable disease is not required. 4. subjects with no other malignancy diagnosed within past five years except for: * cured non-melanoma skin cancer * cured cervical intraepithelial neoplasia (cin) * cured in-situ cervical cancer (cis) 5. subjects who are ecog performance status of ≤ 1
clinical profile of parkinson's disease in patients with hepatitis c infection

Conditions: Parkinson Disease

Summary: there is association between hepatitis c and parkinson's disease as shown from previous studies. the clinical profile and natural history is not fully studied yet. we aim at studying the clinical characteristics of parkinson's disease in patients with hepatitis c infection.


Eligibility criteria:
inclusion criteria: * patient with history of parkinson's disease and hepatitis c infection. exclusion criteria: * advanced liver cirrhosis. * patients with hepatic failure. * symptoms of parkinson's plus syndrome.
clinical study of antiviral therapy combined with novel immunotherapy for chb in adults

Conditions: Chronic Hepatitis b; Immunotherapy

Summary: establish a study cohort of adult chronic hepatitis b antiviral treatment based on the principle of responseguidedtreatment (rgt) corresponding to the child cohort, analyze the clinical cure factors of ic and it stage adults chronic hepatitis b, and optimize the antiviral treatment plan. to determine the safety and efficacy of pd-1 antibody combined with peg-fna-2b in the treatment of adult nas patients with chb advantage.

this research group established an adult randomized controlled study cohort corresponding to the children cohort: 1 immunetolerance (it) and 1 immuneclearance (ic) antiviral treatment cohort, respectively according to 1: 1 randomly divided into two intervention groups: nucleoside (acid) analogues (nas) and nas combined with pegylated interferon α-2b (pegifnα-2b). 1 nas treatment-advantaged population antiviral combined with novel immunotherapy cohort: pd-1 antibody, pegifnα-2b and combination group were randomly enrolled 1:1:1, and the response guidance treatment plan was adjusted according to the response of patients during treatment, the hbsag clearance rate at 24 weeks and 48 weeks of different optimal treatment groups was evaluated, the clinical curative characteristics and differences between children and adults were compared, and the key factors affecting clinical cure were screened. to determine the safety and efficacy of pd-1 antibody combined with peg-fna-2b in the treatment of adult nas patients with chb advantage.

Eligibility criteria:
inclusion criteria: * age 18-65 years old； * meet the 2022 chronic hepatitis b guidelines definition of chronic hbv infection: hbsag and/or hbvdna positive \>6 months;； * immune clearance period: hbeag positive, hbvdna positive, alt\>40u/l; * newly treated patients; * willing to sign informed consent exclusion criteria: * patients with hav, hcv, hev infection and autoimmune liver disease; pregnant and lactating women and patients who plan to give birth in the near future; * patients with cirrhosis or liver cancer indicated by imaging or liver hardness testing; * a history of serious heart disease, including unstable or uncontrolled heart disease within the last 6 months; * have a mental illness or history of mental illness; * have uncontrolled seizures; * alcoholics or drug users who have not abstained; * have uncontrolled diabetes, hypertension, thyroid disease, retinopathy, autoimmune disease, etc.
a randomized study to compare the efficacy and safety of belotecan and topotecan as monotherapy for sensitive-relapsed small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of belotecan administered 5 days every 3 weeks in comparison to topotecan in patients with relapsed small cell lung cancer.

a phase ⅱb, randomized, open, parallel-group, multi-center trial to assess the efficacy and safety of belotecan(camtobell inj.) or topotecan in patients with relapsed small cell lung cancer

Eligibility criteria:
inclusion criteria: * at least 18 years of age * histological or cytological diagnosis of sclc * limited disease (ld) or extensive disease (ed) at time of study entry * recurrent or progressive sclc ≥ 90 days of duration of response for firstline therapy * measurable disease defined by recist criteria * ecog performance status of 0, 1, or 2 * life expectancy ≥ 3 months * adequate bone marrow, renal, hepatic reserve: absolute neutrophil (segmented and bands) count (anc) ≥ 1500 cells/mm3 platelet count ≥ 100,000 cells/ mm3 hemoglobin ≥ 9 g/dl total bilirubin ≤ 1.5 mm3 alanine aminotransferase (alt) and aspartate aminotransferase(ast) ≤ 2.0 x uln alkaline phosphatase (alp) ≤ 2.0 x uln serum creatinine ≤ 1.5mg/dl or calculated creatinine clearance \> 60ml/min - signed a written informed consent exclusion criteria: * active infection * symptomatic brain lesion * any other type of cancer during the previous 5 years * severe concurrent diseases * prior anticancer therapy within 4 weeks before enroll * active pregnancy test and pregnant or nursing women * participation in any investigational drug study within 28 days prior to study entry

Keywords: small cell lung cancer belotecan topotecan
study of cardiac and paroxysmal abnormalities in rett syndrome

Conditions: Rett Syndrome

Summary: objectives: i. evaluate electrocardiographic parameters, including qt and pr intervals and qrs morphology/duration, across clinical stages in patients with rett syndrome. ii. characterize abnormalities of cardiac conduction and repolarization. iii. assess arrhythmias, heart rate variability, and autonomic nervous system function in these patients using 24-hour holter monitoring. iv. record events believed to represent seizures with video, electroencephalogram (eeg), and polygraph monitoring in patients who have more than 1 clinical seizure every 5 days. v. characterize these events with respect to clinical manifestations, eeg correlates, and other physiologic data. vi. determine the frequency of seizures vs. events without electrographic correlates in these patients. vii. determine whether rett syndrome patients have characteristic or unique types of seizures and/or an epileptic syndrome.

protocol outline: patients receive an electrocardiogram at baseline and every 6 months for 3 years. clinical stage ii patients undergo 24-hour holter monitoring on the same schedule; age-matched controls are tested once. a group of patients with more than 1 seizure or possible seizure every 5 days undergo 5-day continuous electroencephalogram/polygraphic/video monitoring, with respiratory effort assessment, end tidal carbon dioxide and oxygen saturation levels, and a seizure log.

Eligibility criteria:
* classical rett syndrome meeting rett syndrome diagnostic work group criteria * age-matched girls without neurologic or cardiac problems entered as controls

Keywords: rett syndrome neurologic and psychiatric disorders rare disease
a study of the combination of oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy in the adjuvant setting in operated participants with human epidermal growth factor receptor-2 positive (her2+) gastric or gastroesophageal junction cancer

Conditions: Gastric Cancer; Gastroesophageal Junction Cancer

Summary: this single-arm, open-label study will evaluate the safety and efficacy of the combination oxaliplatin, capecitabine, and trastuzumab with chemoradiotherapy in the adjuvant setting in participants with curatively resected her2+ gastric or gastroesophageal junction cancer. participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenously (iv) on day 1 of cycle 1 and 6 mg/kg iv on day 1 of every following 3-week cycle, with oxaliplatin 100 milligrams per square meter (mg/m\^2) iv on day 1 of cycles 1-3, and capecitabine 850 mg/m\^2 orally twice daily on days 1-14 of cycles 1-3 and on 5 days per week during chemoradiotherapy. radiotherapy will be given at a total dose of 45 gray (gy) divided into 25 doses on 5 treatment days each week for 5 weeks starting day 22 of cycle 3. anticipated time on study treatment is 1 year plus a 1-year follow-up period.


Eligibility criteria:
inclusion criteria: * curatively resected her2+ gastric or gastroesophageal junction adenocarcinoma; her2+ status as defined by immunohistochemistry-2 positive or 3 positive with corroborative fluorescence in situ hybridization+ result * participants with stages between stage ib (t1n1m0) and stage iiic * ecog performance status score equal to or less than (\<=) 2 during screening * left ventricular ejection fraction equal to or higher than (\>=) 55% with acceptable levels of liver and renal functions * no known contraindication to capecitabine, oxaliplatin, and trastuzumab * no contraindication for radiotherapy or has not received any previous radiotherapy to the gastric region for any reason exclusion criteria: * participants with a malign condition in the last 5 years except squamous cell carcinoma of the skin * previous neoadjuvant chemotherapy and/or radiotherapy * any disruption in the physical integrity of the upper gastrointestinal tract (except surgical intervention for gastric or gastroesophageal junction carcinoma) * known (previously diagnosed and ongoing) malabsorption syndrome * active gastrointestinal bleeding * participants with stage iv gastric or gastroesophageal junction adenocarcinoma * clinically significant cardiac or cardiovascular disease * uncontrolled hypertension * participants who have received any investigational anti-cancer treatment or are being treated in a concomitant investigational drug study * abnormal laboratory values at screening for serum total bilirubin, alanine aminotransferase or aspartate amino transferase, alkaline phosphatase, absolute neutrophil count, platelet count, and/or hemoglobin * known or suspected hypersensitivity against trastuzumab or proteins of rodents * pregnancy or lactation
comparing intubation rates in the delivery room by interface

Conditions: Ventilator Lung; Newborn

Summary: although the majority of premature neonates \< 30 weeks gestion require positive pressure ventilation (ppv) at birth, the optimal interface to provide ppv has not been determined. preferably this support would be provided by non-invasive means to prevent the development of bronchopulmonary dysplasia. resuscitation with a face mask, single nasal tube, nasal prongs, and/or lma are all approved methods of resuscitation per nrp as of 2010. face masks have been associated with more dead space, air leak and airway obstruction however are the most commonly used interface. recently, the trigeminal cardiac reflex has been described, which can be induced with the placement of a facemask, resulting in bradycardia and apnea. bi-nasal prongs (ram cannula) have been found in studies to be associated with lower intubation rates in the delivery room (down to 24 weeks gestation), less need for epinephrine, chest compressions, and subsequent invasive ventilation. in addition to the potential practical advantages of bi-nasal prong resuscitation, there is evidence to suggest that ventilation through the nose may stimulate the subepithelial receptors of the upper airways causing an increase in respiratory rate and depth.


Eligibility criteria:
inclusion criteria: all resuscitated infants \< 30 weeks' gestation born at osf sfmc exclusion criteria: diagnosis of congenital diaphragmatic hernia no ppv needed, or no resuscitation desired due to major congenital anomalies or peri- viable status
percutaneous electrical nerve stimulation compared to passive assisted neurodynamics in brachial plexus neuropathy

Conditions: Percutaneous Electrical Nerve Stimulation; Peripheral Neuropathy; Neuropathic Pain

Summary: brachial plexus neuropathies, specifically of the median, radial, ulnar, suprascapular, axillary and dorsal scapular nerves, can arise when a peripheral nerve trunk or nerve root is subjected to injury, compression, inflammation or ischemia, resulting in reduced physical capabilities of the peripheral nervous system. although pharmacological treatments provide mild symptomatic relief in the short term, they are not without side effects. neurostimulation techniques may be an effective treatment option for peripheral brachial plexus neuropathies. some of these procedures are transcutaneous electrical nerve stimulation (tens) or percutaneous electrical nerve stimulation (pens). although some case series have documented a positive effect in relation to ultrasound-guided pens for subjects with subacromial pain syndrome or postsurgical pain, the lack of studies, to our knowledge, analyzing the effects of percutaneous electrical nerve stimulation, in relation to pain and paresthesias in subjects with brachial plexus neuropathy, warrants investigation for this goal.


Eligibility criteria:
inclusion criteria: * subjects with upper limb neural symptomatology between 18 and 60 years of age, presenting two or more of the following conditions: * paresthesias in any territory of the shoulder girdle, arm or hand * pain at rest in any territory of the upper extremity. * pain at rest in any upper extremity territory * sensations of electric shock in any territory of the shoulder girdle, arm or hand. * allodynia or cutaneous hyperalgesia in any territory of the shoulder girdle, arm or hand. exclusion criteria: * less than 2 weeks of evolution * fracture in the affected upper extremity * suffering from another joint disorder such as osteoarthritis or rheumatic disease * suffering from generalized neuropathies due to neuromuscular disease or medication * inability to understand instructions or sign informed consent. * wearing a pacemaker or any electrical device implanted in the body * epilepsy * aversion or fear of needles * pregnant.